MedTrace Logo

CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness

NCT03652181 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 123

Last updated 2024-06-27

Study results available
· View outcomes & findings →

Summary

Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy. This trial readiness project aims to address current critical obstacles in identifying cases at multiple sites, characterizing their relevant features, and measuring their outcome. The timing cannot be more opportune, with therapeutic targets already identified, exceptional collaboration among researchers and with the patient community, and several drugs ready to benefit from a track to clinical testing in the next five years.

Conditions

  • CCM
  • Cavernoma
  • Cerebral Cavernous Malformation
  • Cerebral Cavernous Malformations 1
  • Cerebral Cavernous Malformations 2
  • Cerebral Cavernous Malformations 3
  • Cavernous Angioma

Sponsors & Collaborators

Principal Investigators

  • Issam A Awad, MD · University of Chicago

  • Daniel Hanley, MD · Johns Hopkins University

  • Kelly Flemming, MD · Mayo Clinic

  • Helen Kim, MPH, PhD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2022-11-03
Completion
2022-11-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03652181 on ClinicalTrials.gov